LOS ANGELES--(BUSINESS WIRE)--Abviva, Inc. (f/k/a Genesis Bioventures: OTCBB:GBIW) today announced that it has entered into a Letter of Intent with the Receiver for Efoora, Inc. appointed by the United States District Court For The Northern District of Illinois Eastern Division (the “Court”) to acquire all Prion Developmental Laboratories, (“PDL”) stock owned by Efoora, Inc., PDL’s current majority owner. The acquisition is subject to Abviva’s due diligence, final approval by Abviva’s Board of Directors and entry of an order approving the sale by the Court.
